Molecular structure of Idarubicin Hydrochloride, CAS Number: 57852-57-0
Idarubicin Hydrochloride (CAS 57852-57-0)
See product citations (2)
Alternate Names:
4-Demethoxydaunorubicin; Zavedos
Application:
Idarubicin Hydrochloride is an apoptosis inducer
CAS Number:
57852-57-0
Purity:
≥98%
Molecular Weight:
533.95
Molecular Formula:
C26H27NO9•HCl
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Idarubicin Hydrochloride is the hydrochloride salt preparation of Idarubicin (IDA), an anthracycline and an analog of daunorubicin (sc-218089). IDA is rapidly metabolized to its 13-dihydroderivative (Idarubicinol) which is more stable than the parent form. This compound has been reported to trigger apoptotic cell death via enhancement of Fas and caspase-3/caspase-7 expression. In experiments, where cells were exposed to IDA, reactive oxygen species (ROS) were produced which induced DNA strand breaks and prevented DNA polymerase reaction. Idarubicin Hydrochloride is an inhibitor of Topo II alpha. Idarubicin Hydrochloride is also a substrate of CYP2D6 and CYP2C9.
Idarubicin Hydrochloride (CAS 57852-57-0) References
- Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment. | Belaud-Rotureau, MA., et al. 2000. Leukemia. 14: 1266-75. PMID: 10914552
- A HPLC method for the simultaneous determination of seven anthracyclines. | Badea, I., et al. 2005. J Pharm Biomed Anal. 39: 305-9. PMID: 15935598
- Damage to the cell antioxidative system in human erythrocytes incubated with idarubicin and glutaraldehyde. | Marczak, A. and Jóźwiak, Z. 2009. Toxicol In Vitro. 23: 1188-94. PMID: 19490936
- Control of retention mechanisms on an octadecyl-bonded silica column using ionic liquid-based mobile phase in analysis of cytostatic drugs by liquid chromatography. | Treder, N., et al. 2021. J Chromatogr A. 1651: 462257. PMID: 34090057
- Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. | Ganzina, F., et al. 1986. Invest New Drugs. 4: 85-105. PMID: 3516918
- Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases. | Afowowe, TO., et al. 2022. Viruses. 15: PMID: 36680145
- Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. | Fukushima, T., et al. 1993. Int J Hematol. 57: 121-30. PMID: 8494991
- Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia. | Tsuruo, T., et al. 1993. Anticancer Res. 13: 357-61. PMID: 8517647
Inhibitor of:
Topo II alpha.Substrate of:
CYP2C9, and CYP2D6.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Idarubicin Hydrochloride, 1 mg | sc-204774 | 1 mg | $72.00 | |||
Idarubicin Hydrochloride, 5 mg | sc-204774A | 5 mg | $170.00 | |||
Idarubicin Hydrochloride, 10 mg | sc-204774B | 10 mg | $269.00 | |||
Idarubicin Hydrochloride, 50 mg | sc-204774C | 50 mg | $740.00 |